Relationship between serum expression levels of miR-214-3p and miR-124-3p and the severity of disease in patients with Parkinson's disease and their values in early diagnosis

doi:10.11958/20250429

Abstract

Abstract:

Objective To analyze the relationship between the expression levels of serum microRNA-214-3p and miR-124-3p with the severity of Parkinson's disease (PD), and their early diagnostic value. Methods From January 2018 to December 2023, 96 PD patients admitted to Rugao Traditional Chinese Medicine Hospital were selected as the PD group, and 106 healthy individuals were selected as the control group. According to the severity of 96 patients, they were grouped into the early stage group (I-II stage, n=59）and the mid to late stage group (III-V stage, n=37). RT-qPCR was applied to detect serum levels of miR-214-3p and miR-124-3p. Spearman method was used for correlation analysis. The influencing factors of PD severity were analyzed using multiple Logistic regression analysis. The efficacy of serum miR-214-3p and miR-124-3p in diagnosing PD and its severity was analyzed by receiver operating characteristics (ROC). Results Compared with the control group, the serum levels of miR-214-3p and miR-124-3p were lower in the PD group (P<0.05). Compared with the early stage group, there were a longer disease course, higher level of homocysteine (Hcy) and lower levels of serum miR-214-3p and miR-124-3p in the mid to late stage group (P<0.05). Spearman analysis showed that serum miR-214-3p and miR-124-3p were negatively correlated with Hoehn-Yahr staging in PD patients (P<0.05). Multivariate Logistic regression showed that disease duration (OR=1.249), Hcy (OR=1.156), serum miR-214-3p (OR=0.925) and miR-124-3p (OR=0.917) were factors influencing the severity of PD (P<0.05). ROC analysis showed that the sensitivity and specificity of serum miR-214-3p and miR-124-3p combined in the diagnosis of PD were 85.42% and 81.90% respectively. The sensitivity and specificity of serum miR-214-3p and miR-124-3p in the diagnosis of advanced PD were 89.16% and 79.66% respectively. Conclusion The serum levels of miR-214-3p and miR-124-3p are relatively low in PD patients, and their levels are related to the severity of disease. The detection of serum miR-214-3p and miR-124-3p is helpful for the diagnosis and evaluation of PD.

Key words: Parkinson disease, microRNAs, ROC curve, severity, miR-214-3p, miR-124-3p

CLC Number:

R742.5

Figures/Tables 8

References 22

[1]	KUMAR S, GOYAL L, SINGH S. Tremor and rigidity in patients with Parkinson's disease:emphasis on epidemiology,pathophysiology and contributing factors[J]. CNS Neurol Disord Drug Targets, 2022, 21(7):596-609. doi:10.2174/1871527320666211006142100.
[2]	翟书鹏, 贾航, 苗统, 等. 帕金森病患者血清Trx1、PDCD4、AQP4水平与认知功能的关系[J]. 天津医药, 2025, 53(2):146-150.
	ZHAI S P, JIA H, MIAO T, et al. The relationship between serum Trx1,PDCD4,AQP4 expression and cognitive function in patients with Parkinson's disease[J]. Tianjin Med J, 2025, 53(2):146-150. doi:10.11958/20241632.
[3]	RODRIGUES-COSTA M, FERNANDES M S S, JUREMA-SANTOS G C, et al. Nutrigenomics in Parkinson's disease:diversity of modulatory actions of polyphenols on epigenetic effects induced by toxins[J]. Nutr Neurosci, 2023, 26(1):72-84. doi:10.1080/1028415X.2021.2017662.
[4]	WALKER L, ATTEMS J. Prevalence of concomitant pathologies in Parkinson's disease:implications for prognosis,diagnosis,and insights into common pathogenic mechanisms[J]. J Parkinsons Dis, 2024, 14(1):35-52. doi:10.3233/JPD-230154.
[5]	SALEEM A, JAVED M, AKHTAR M F, et al. Current updates on the role of microRNA in the diagnosis and treatment of neurodegenerative diseases[J]. Curr Gene The, 2024, 24(2):122-134. doi:10.2174/0115665232261931231006103234.
[6]	LI L, WANG H, LI H, et al. Long noncoding RNA BACE1-antisense transcript plays a critical role in Parkinson's disease via microRNA-214-3p/Cell death-inducing p53-target protein 1 axis[J]. Bioengineered, 2022, 13(4):10889-10901. doi:10.1080/21655979.2022.2066750.
[7]	ESTEVES M, CRISTOVAO A C, VALE A, et al. MicroRNA-124-3p modulates alpha-synuclein expression levels in a paraquat-induced in vivo model for Parkinson's disease[J]. Neurochem Res, 2024, 49(7):1677-1686. doi:10.1007/s11064-024-04130-y.
[8]	中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49(4):268-271.
	Parkinson's Disease and Movement Disorders Group,Chinese Society of Neurology. Diagnostic criteria for Parkinson's disease in China(2016 edition)[J]. Chinese Journal of Neurology, 2016, 49(4):268-271. doi:10.3760/cma.j.issn.1006-7876.2016.04.002.
[9]	KATAOKA H, SUGIE K. Association between fatigue and Hoehn-Yahr staging in Parkinson's disease:eightyear follow-up study[J]. Neurol Int, 2021, 13(2):224231-224240. doi:10.3390/neurolint13020023.
[10]	ZHENG Z, ZHU Z, ZHOU C, et al. Burden of Parkinson disease in China,1990-2019:findings from the 2019 global burden of disease study[J]. Neuroepidemiology, 2023, 57(1):51-64. doi:10.1159/000527372.
[11]	KHAN M A, HAIDER N, SINGH T, et al. Promising biomarkers and therapeutic targets for the management of Parkinson's disease:recent advancements and contemporary research[J]. Metab Brain Dis, 2023, 38(3):873-919. doi:10.1007/s11011-023-01180-z.
[12]	LIU J, ZHANG H, DI K, et al. Circular noncoding RNA circ-0007865,serves as a competing endogenous RNA,targeting the miR-214-3p/FKBP5 axis to regulate oxygen-glucose deprivation-induced injury in brain microvascular endothelial cells[J]. Neuroreport, 2022, 33(4):163-172. doi:10.1097/WNR.00000000000001751.
[13]	燕佳辉. miR-214-3p调控ATG3影响多巴胺能神经元功能参与PD发病机制的研究[D]. 郑州: 郑州大学, 2022.
	YAN J H. miR-214-3p regulates ATG3,affects dopaminergic neuron function and participates in the pathogenesis of PD[D]. Zhengzhou: Zhengzhou University, 2022. doi:10.27466/d.cnki.gzzdu.2022.000765.
[14]	杜姝, 傅增辉, 姜岩, 等. 基于Fas/FasL信号通路探究调控miR-214-3p对帕金森病大鼠的干预效果[J]. 中国老年学杂志, 2023, 43(17):4290-4294.
	DU S, FU Z H, JIANG Y, et al. To explore the intervention effect of regulating miR-214-3p on Parkinson's disease rats based on Fas/FasL signaling pathway[J]. Chinese Journal of Gerontology, 2023, 43(17):4290-4294. doi:10.3969/j.issn.1005-9202.2023.17.052.
[15]	LIAO Y, GU Y, WANG J, et al. HSF1 inhibits microglia activation to attenuate neuroinflammation via regulating miR-214-3p and NFATc2 in Parkinson's disease[J]. Folia Neuropathol, 2023, 61(1):53-67. doi:10.5114/fn.2022.122800.
[16]	李彦霖, 王有民, 朱莉. miR-124在常见神经退行性疾病中的作用[J]. 南京医科大学学报(自然科学版), 2024, 44(1):123-129.
	LI Y L, WANG Y M, ZHU L. Roles of miR-124 in neurodegenerative diseases[J]. Journal of Nanjing Medicial University(Natural Sciences), 2024, 44(1):123-129. doi:10.7655/NYDXBNSN230703.
[17]	WANG Y, LI D, ZHANG L, et al. Exosomes derived from microglia overexpressing miR-124-3p alleviate neuronal endoplasmic reticulum stress damage after repetitive mild traumatic brain injury[J]. Neural Regen Res, 2024, 19(9):2010-2018. doi:10.4103/1673-5374.391189.
[18]	罗丹, 吴继祥, 覃国勇, 等. 帕金森病患者血清miR-124水平与认知损害、炎症及氧化应激反应的相关性[J]. 国际检验医学杂志, 2022, 43(18):2249-2254.
	LUO D, WU J X, QIN G Y, et al. Correlation of serum miR-124 level with cognitive impairment and inflammatory oxidative stress response in patients with Parkinson's disease[J]. International Journal of Laboratory Medicine, 2022, 43(18):2249-2254. doi:10.3969/j.issn.1673-4130.2022.18.015.
[19]	ZHANG Y J, ZHU W K, QI F Y, et al. CircHIPK3 promotes neuroinflammation through regulation of the miR-124-3p/STAT3/NLRP3 signaling pathway in Parkinson's disease[J]. Adv Clin Exp Med, 2023, 32(3):315-329. doi:10.17219/acem/154658.
[20]	FAN J, WU D, GUO Y, et al. SOS1-IT1 silencing alleviates MPP+-induced neuronal cell injury through regulating the miR-124-3p/PTEN/AKT/mTOR pathway[J]. J Clin Neurosci, 2022, 99(1):137-146. doi:10.1016/j.jocn.2022.01.003.
[21]	PHOKAEWVARANGKUL O, BHIDAYASIRI R, GARCIA-RUIZ P, et al. Homocysteine,vitamin B metabolites,dopamine-substituting compounds,and symptomatology in Parkinson's disease:clinical and therapeutic considerations[J]. J Neural Transm(Vienna), 2023, 130(11):1451-1462. doi:10.1007/s00702-023-02684-9.
[22]	黄琦, 沈慧, 李文, 等. 帕金森病病人血清25-羟维生素D、Hcy水平与运动、非运动症状的相关性分析[J]. 中西医结合心脑血管病杂志, 2024, 22(5):938-941.
	HUANG Q, SHEN H, LI W, et al. Correlation analysis of serum 25-hydroxyvitamin D and Hcy levels with motor and non-motor symptoms in patients with Parkinson's disease[J]. Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, 2024, 22(5):938-941. doi:10.12102/j.issn.1672-1349.2024.05.033.

组别	n	miR-214-3p	miR-124-3p
对照组	106	0.98±0.19	1.01±0.20
PD组	96	0.74±0.14	0.82±0.16
t		10.130^＊＊	7.406^＊＊

组别	n	miR-214-3p	miR-124-3p
对照组	106	0.98±0.19	1.01±0.20
PD组	96	0.74±0.14	0.82±0.16
t		10.130^＊＊	7.406^＊＊

组别	n		性别						年龄/岁		体质量指数/（kg/m²）				受教育程度							吸烟史			饮酒史
组别	n		男			女			年龄/岁		体质量指数/（kg/m²）				初中及以下		高中/中专			专科及以上		吸烟史			饮酒史
早期组	59		26（44.07）			33（55.93）			68.53±7.05		22.76±2.31				20（33.90）		27（45.76）			12（20.34）		21（35.59）			18（30.51）
中晚期组	37		19（51.35）			18（48.65）			69.65±7.18		23.07±2.38				18（48.65）		13（35.14）			6（16.22）		17（45.95）			15（40.54）
t或χ²			0.484						0.752		0.633				2.072							1.014			1.014
组别		糖尿病史			高血压史			高脂血症史				临床分型							起病侧
组别		糖尿病史			高血压史			高脂血症史				震颤型	强直型			混合型			左侧		右侧			双侧
早期组		9（15.25）			24（40.68）			15（25.42）				19（32.20）	14（23.73）			26（44.07）			19（32.20）		25（42.37）			15（25.42）
中晚期组		10（27.03）			17（45.95）			13（35.14）				13（35.14）	10（27.03）			14（37.84）			9（4.32）		15（40.54）			13（35.14）
χ²		1.985			0.258			1.038				0.369							1.238
组别				病程/月			TG/（mmol/L）			TC/（mmol/L）				LDL-C/（mmol/L）				HDL-C/（mmol/L）					Hcy/（μmol/L）
早期组				26.49±5.37			1.27±0.24			4.52±0.61				1.76±0.38				1.13±0.25					16.37±3.86
中晚期组				37.81±7.21			1.33±0.29			4.59±0.65				1.82±0.43				1.04±0.21					21.05±4.63
t				8.791^＊＊			1.099			0.534				0.716				1.823					5.350^＊＊

组别	n		性别						年龄/岁		体质量指数/（kg/m²）				受教育程度							吸烟史			饮酒史
组别	n		男			女			年龄/岁		体质量指数/（kg/m²）				初中及以下		高中/中专			专科及以上		吸烟史			饮酒史
早期组	59		26（44.07）			33（55.93）			68.53±7.05		22.76±2.31				20（33.90）		27（45.76）			12（20.34）		21（35.59）			18（30.51）
中晚期组	37		19（51.35）			18（48.65）			69.65±7.18		23.07±2.38				18（48.65）		13（35.14）			6（16.22）		17（45.95）			15（40.54）
t或χ²			0.484						0.752		0.633				2.072							1.014			1.014
组别		糖尿病史			高血压史			高脂血症史				临床分型							起病侧
组别		糖尿病史			高血压史			高脂血症史				震颤型	强直型			混合型			左侧		右侧			双侧
早期组		9（15.25）			24（40.68）			15（25.42）				19（32.20）	14（23.73）			26（44.07）			19（32.20）		25（42.37）			15（25.42）
中晚期组		10（27.03）			17（45.95）			13（35.14）				13（35.14）	10（27.03）			14（37.84）			9（4.32）		15（40.54）			13（35.14）
χ²		1.985			0.258			1.038				0.369							1.238
组别				病程/月			TG/（mmol/L）			TC/（mmol/L）				LDL-C/（mmol/L）				HDL-C/（mmol/L）					Hcy/（μmol/L）
早期组				26.49±5.37			1.27±0.24			4.52±0.61				1.76±0.38				1.13±0.25					16.37±3.86
中晚期组				37.81±7.21			1.33±0.29			4.59±0.65				1.82±0.43				1.04±0.21					21.05±4.63
t				8.791^＊＊			1.099			0.534				0.716				1.823					5.350^＊＊

组别	n	miR-214-3p	miR-124-3p
早期组	59	0.81±0.15	0.89±0.17
中晚期组	37	0.63±0.12	0.72±0.14
t		6.163^＊＊	5.093^＊＊